ArticleJournal of tropical medicine2011
Current evidence on the use of antifilarial agents in the management of bancroftian filariasis.
Article in Journal of tropical medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 37 citations in OpenAlex.
- An Overview on Antifilarial Efficacy of Heterocyclic Motifs Encompassing Synthetic Strategies, SAR and Commercialized Medications.Current topics in medicinal chemistry · 2025Review
- Case Report: Allergic Bronchopulmonary Aspergillosis and Tropical Pulmonary Eosinophilia Co-Occurrence Masquerading as Refractory Allergic Bronchopulmonary Aspergillosis.The American journal of tropical medicine and hygiene · 2024Article
- Article
- Elimination of diurnally sub-periodic Wuchereria bancrofti in Andaman and Nicobar Islands, India, using mass DEC-fortified salt as a supplementary intervention to MDA.Parasitology research · 2020Article
- Comparison of efficacy of ivermectin and diethylcarbamazine against naturally infectedJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2019Article
- Killing filarial nematode parasites: role of treatment options and host immune response.Infectious diseases of poverty · 2016Review
- Antifilarial and Antibiotic Activities of Methanolic Extracts of Melaleuca cajuputi Flowers.The Korean journal of parasitology · 2016Article
- A bipolar disorder patient becoming asymptomatic after adjunctive anti-filiarasis treatment: a case report.BMC psychiatry · 2013Article
- Relevance of the eosinophil blood count in bancroftian filariasis as a screening tool for the treatment.Pathogens and global health · 2013Article
- Arbonematodes - nematode infections transmissible by arthropods: arbeitskreis blut, untergruppe «bewertung blutassoziierter krankheitserreger»*.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2013Article
- A cell-based screen reveals that the albendazole metabolite, albendazole sulfone, targets Wolbachia.PLoS pathogens · 2012Article
- The impact of mass drug administration and long-lasting insecticidal net distribution on Wuchereria bancrofti infection in humans and mosquitoes: an observational study in northern Uganda.Parasites & vectors · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many trials have explored the efficacy of individual drugs and drug combinations to treat bancroftian filariasis. This narrative review summarizes the current evidence for drug management of bancroftian filariasis. Diethylcarbamazine (DEC) remains the prime antifilarial agent with a well-established microfilaricidal and some macrofilaricidal effects. Ivermectin (IVM) is highly microfilaricidal but minimally macrofilaricidal. The role of albendazole (ALB) in treatment regimens is not well established though the drug has a microfilaricidal effect. The combination of DEC+ALB has a better long-term impact than IVM+ALB. Recent trials have shown that doxycycline therapy against Wolbachia, an endosymbiotic bacterium of the parasite, is capable of reducing microfilaria rates and adult worm activity. Followup studies on mass drug administration (MDA) are yet to show a complete interruption of transmission, though the infection rates are reduced to a very low level.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.